HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Quantitative morphological assessment of erythroblastic differentiation induced, in vitro, in human K562 leukemic cells.

Abstract
K562 human leukemia cell line undergoes in vitro terminal differentiation towards the erythroid pathway following treatments with appropriate chemical agents including aclacinomycin, fagaronine and hemin. These three drugs induced a different expression of phenotypic and functional characters associated with differentiation. The morphological characteristics of the differentiation sequences elicited by these agents were evaluated by image analysis using a SAMBA 200 cell image processor. Multivariate statistical analyses of morphological data revealed that only aclacinomycin was able to induce significant modifications of the morphological parameters similar to those observed during the maturation of normal bone-marrow erythroblastic cells. These data correlate with the higher inductive potency of aclacinomycin as compared to hemin or fagaronine and suggest that quantitative cytology may be a useful adjunct to conventional tests for the selection of new drugs with differentiating potential.
AuthorsC Broglio, J Dufer, P Joly, Y Carpentier, A Desplaces
JournalAnalytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology (Anal Cell Pathol) Vol. 5 Issue 3 Pg. 135-46 (May 1993) ISSN: 0921-8912 [Print] Netherlands
PMID8343432 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Alkaloids
  • Benzophenanthridines
  • Hemoglobins
  • Phenanthridines
  • aclacinomycins
  • fagaronine
  • Hemin
  • Aclarubicin
Topics
  • Aclarubicin (analogs & derivatives, pharmacology)
  • Alkaloids (pharmacology)
  • Benzophenanthridines
  • Cell Differentiation (drug effects)
  • Erythroblasts (drug effects, pathology)
  • Hemin (pharmacology)
  • Hemoglobins (biosynthesis)
  • Humans
  • Leukemia (pathology)
  • Phenanthridines
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: